MRK Stock Price Today (October 2026) — Merck & Co., Inc. Analysis & Key Metrics 2026-10-07
Merck & Co., Inc. (MRK) is trading at $142.79, up 0.60% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $155.76 (9.1% upside).
- Volatility is low (20.16% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.10% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
MRK Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Merck & Co., Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $399.06B
P/E Ratio
Forward P/E: 15.48
Revenue Growth
Year over Year
Analyst Target
+9.1% upside potential
Key Investor Questions About MRK
What investors need to know before buying
Based on current market data, MRK presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 42.38)
- Fundamentals say: Looking solid (debt and growth supportive)
MRK's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRK investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $53.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, MRK stock traded between $82.01 and $156.92 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.16% annualized volatility and β=0.34, the stock exhibits low sensitivity to market moves—making MRK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval
Merck’s stock has had a strong multi year run, and with the shares closing at US$148.78 most recently, the key question for you is whether that level is supported by the cash the business can generate over time. Over the past 5 years, Merck has delivered a total return of 113.0%, which puts real weight on the question of whether the current valuation still lines up with its underlying cash flows. Recent approvals and label expansions for treatments such as Welireg combinations, WINREVAIR and...
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
Merck remigromig DME trial results raise safety concerns
Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications
Bank of America has strong message for Merck stock investors
A private meeting with the drugmaker’s top doctor points to the next make-or-break moment for shareholders.
Merck Jumps as Winrevair Moves Earlier in PAH
The label now includes evidence from newly diagnosed patients, widening confidence before revealing commercial uptake.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
3 Reasons to Sell MRK and 1 Stock to Buy Instead
Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Explore More Analysis for MRK
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Merck & Co., Inc.
Merck & Co., Inc. (MRK) is currently trading at $142.79. The RSI (14-day) is at 42.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $155.76 implies 9.1% upside from current levels. Volatility is moderate at 20.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Merck & Co., Inc. (MRK): The trailing P/E ratio is 115.88, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.48, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 10.26, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 8.53. Price-to-Sales is 5.37. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering MRK, the consensus price target is $155.76. This represents a 9.1% upside from the current price of $142.79. The range spans from a low target of $105.00 to a high target of $186.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Merck & Co., Inc. (MRK) pays a dividend with a current yield of approximately 2.38%. The annualized dividend rate is $3.32 per share. The payout ratio is 268.8%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was Sep 15, 2026.
Key risks for Merck & Co., Inc. (MRK) investors include: 1. Elevated debt levels (debt-to-equity of 1.28x) which could pressure margins in a rising rate environment. 2. Unsustainable dividend payout ratio (269%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Merck & Co., Inc.'s (MRK) current debt and financial health profile: Total debt stands at $53.91B. The debt-to-equity ratio is 1.28x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.32, indicating adequate short-term liquidity. The quick ratio is 0.74. The company holds $7.14B in cash and equivalents. Free cash flow is positive at $15.17B, providing a cushion for debt servicing and shareholder returns.